Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFDA Said Considering Shortening Oncology Drug INDs To 60 Days

This article was originally published in PharmAsia News

Executive Summary

In one reform after another, the China FDA is acting swiftly to accelerate new drug approvals, this time with a focus on innovative cancer therapies. The agency is said to be planning a pilot scheme that would change the current investigational new drug (IND) process from an approval to a filing mechanism, and set 60 days as the timeframe.

You may also be interested in...



Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Gene Editing In China: EdiGene Raises Fresh Funds, Aims For First IND

With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.

China Regulatory Express: New Cell Therapy, Gene Editing Guidelines Proposed

Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel